100s of titles, one news app for just $10 a month.
Dive Deeper:
Raymond James Says 'Supply Chain Challenges Made Q1 Messy' For This Medtech Stock
ICU Medical Inc (NASDAQ:ICUI) reported Q1 sales of $543.1 million vs. Raymond James' estimate of $530 million.  Core ICU beat by $7 million,…
Bumble Shares Soar On Analyst Confidence Post Q1 Beat
Analysts expressed optimism on Bumble Inc (NASDAQ: BMBL) post Q1 beat. Raymond James analyst Andrew Mar
Down 80% in 2022, Is Now a Good Time to Scoop Up Shares of Skillz?
The shares of gaming company Skillz (SKLZ) have plummeted 80% in price this year, indicating investor pessimism. Also, analysts expect…
Read Why Did Raymond James Slash Price Target On Inflarx
Raymond James remains a Strong Buy on Inflarx NV (NASDAQ: IFRX) following 1Q22 earnings based on a promising outlook for vilobelimab in Pyoderma Gangrenosum (PG) and…
One subscription that gives you access to news from hundreds of sites
Why Embecta Shares Are Falling Today
Becton Dickinson and Co's (NYSE:BDX) pure-play diabetes spin-off Embecta Corp (NASDAQ:EMBC) has reported Q2 sales of $274.5 million, down 3.4% on a reported basis,…
HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty
Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125…
Get all your news in one place
Latest Business news:
First Default on Foreign Debt Likely This Week: Sri Lanka Latest
Sri Lanka is sliding into a default as the grace period on two unpaid foreign bonds ends on Wednesday, the…
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
Bitcoin recovers above $30,000, other crypto prices today also surge; Terra cracks 31%
Cryptocurrency Bitcoin staged a modest recovery and was up more than 2%
Elon Musk Takes a Stand in Controversial Disney Copyright Case
The copyright debate has recently been revived by a bill seeking to reduce the term of protection for original works.
Facebook changing with times a decade after stock debut
San Francisco (AFP) - Facebook boss Mark Zuckerberg rang the opening bell remotely to cheers 10 years ago as the…
WA craft brewer Boston Brewery creates wet hop beers to help sustain farms
WA craft brewers are experimenting with wet hop beers that can only be made using freshly harvested, local hops. It…
From analysis to good news, read the world’s best news in one place
Australia's insolvency drought might end with an unwanted flood
As the pandemic roared in during early 2020, rapid and astonishing shifts were made to prop up an economy sledgehammered…
Farming sector 'out of political focus'
Agriculture hasn't had enough attention this election campaign, says the National Farmers' Federation, which has rated party policies affecting farmers.

Raymond James Sees 'Pipeline Key Success Factor' For This MedTech Stock

By Vandana Singh
  • Raymond James has reiterated Outperform rating on LumiraDx Limited's (NASDAQ:LMDX) shares after 1Q revenue beat but lower than expected margins that ultimately do very little to impact long-term views of the company. 
  • They lowered the price target from $9 to $7.
  • Revenues were 7% above Raymond James' view and 12% above consensus.
  • The beat was driven by Fast Lab instead of platform revenues, which were below analyst view but mainly on a lack of instrument revenues as most went into the field free of charge (but associated with material test strip orders). 
  • Gross margins of 39.6% were impaired by 11 points due to instrument placements being fully expensed without matching revenues.
  • The analysts expect the margin dynamics to resolve themselves over time as key strip margins are as expected. 
  • The analyst believes net instrument installs and progress on the pipeline will prove more impactful. 
  • More details should come on the pipeline at the newly announced June investor day. The combination of HbA1c (summer launch in Europe), CRP (launched in Europe), INR (launched in Europe), and COVID-19/flu combo tests (CE mark submission shortly) will already allow the LumiraDx platform to replace three separate instruments in the primary care setting. 
  • Hitting timelines and gaining traction with non-COVID-19 assays will be pivotal into 2H, but 1Q was, for the most part, "so far so good" on this front.
  • Price Action: LMDX shares are up 1.05% at $3.84 during the market session on the last check Thursday.
What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
Raymond James Says 'Supply Chain Challenges Made Q1 Messy' For This Medtech Stock
ICU Medical Inc (NASDAQ:ICUI) reported Q1 sales of $543.1 million vs. Raymond James' estimate of $530 million.  Core ICU beat by $7 million,…
Bumble Shares Soar On Analyst Confidence Post Q1 Beat
Analysts expressed optimism on Bumble Inc (NASDAQ: BMBL) post Q1 beat. Raymond James analyst Andrew Mar
Down 80% in 2022, Is Now a Good Time to Scoop Up Shares of Skillz?
The shares of gaming company Skillz (SKLZ) have plummeted 80% in price this year, indicating investor pessimism. Also, analysts expect…
Read Why Did Raymond James Slash Price Target On Inflarx
Raymond James remains a Strong Buy on Inflarx NV (NASDAQ: IFRX) following 1Q22 earnings based on a promising outlook for vilobelimab in Pyoderma Gangrenosum (PG) and…
One subscription that gives you access to news from hundreds of sites
Why Embecta Shares Are Falling Today
Becton Dickinson and Co's (NYSE:BDX) pure-play diabetes spin-off Embecta Corp (NASDAQ:EMBC) has reported Q2 sales of $274.5 million, down 3.4% on a reported basis,…
HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty
Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125…
Get all your news in one place